Association of Aripiprazole With the Risk for Psychiatric Hospitalization, Self-harm, or Suicide.
Importance: Some reports have raised concerns regarding a potential psychiatric worsening associated with first-time use of aripiprazole in patients already treated with other antipsychotic medications. Whether aripiprazole use, particularly in the long term, increases the risk for serious psychiatric events is unclear.
Objective: To assess whether switching to or adding aripiprazole is associated with serious psychiatric treatment failure compared with switching to or adding another antipsychotic drug in patients previously exposed to antipsychotic medications.
Design, Setting, and Participants: This population-based cohort study was conducted from January 1, 2005, to March 31, 2015. Data were obtained from the United Kingdom Clinical Practice Research Datalink, one of the world's largest computerized databases linked to the Hospital Episodes Statistics repository and the Office for National Statistics (ONS) mortality database. Within a base cohort of new users of antipsychotic drugs, patients switching or adding aripiprazole (n = 1643) were propensity matched 1:1 to patients switching to or adding another antipsychotic medication (n = 1643). All patients were followed up until psychiatric treatment failure, for 365 days (1 year) after cohort entry, until death from any cause other than suicide, until end of registration or linkage with the databases, or end of the study period (March 31, 2016).
Main Outcomes and Measures: Cox proportional hazards regression models were used to estimate hazard ratios (HRs) and 95% CIs of serious events of psychiatric treatment failure (psychiatric hospitalizations, self-harm, or suicide) associated with switching to or adding aripiprazole compared with other antipsychotic drugs. In addition to propensity score matching, all models were adjusted for age, number of psychiatric hospitalizations or self-harm events in the 6 months before cohort entry, number of different antipsychotic drugs before cohort entry, and quintiles of the Index of Multiple Deprivation.
Results: The study cohort included 1643 patients (949 [57.8%] were women with a mean [SD] age of 42.1 [16.8] years) starting aripiprazole use; they were matched 1:1 to 1643 patients (871 [53.0%] were women with a mean [SD] age of 42.4 [17.1] years) starting use of another antipsychotic drug. During 2692 person-years of follow-up, 391 incident serious psychiatric treatment failures occurred, with a crude incidence rate of 14.52 (95% CI, 13.16-16.04) per 100 person-years. First-time use of aripiprazole was not associated with an increased rate of psychiatric treatment failure (HR, 0.87; 95% CI, 0.71-1.06), psychiatric hospitalizations (HR, 0.85; 95% CI, 0.69-1.06), or self-harm or suicide (HR, 0.96; 95% CI, 0.68-1.36) compared with starting use of another antipsychotic drug. Results were consistent across several sensitivity analyses.
Conclusions and Relevance: Initiating aripiprazole use, compared with another antipsychotic medication, after a previous antipsychotic exposure did not appear to be associated with psychiatric hospitalization, self-harm, or suicide; these findings warrant replication in large observational studies.
|投稿者||Montastruc, Francois; Nie, Rui; Loo, Simone; Rej, Soham; Dell'Aniello, Sophie; Micallef, Joelle; Suissa, Samy; Renoux, Christel|
|組織名||Centre for Clinical Epidemiology, Lady Davis Research Institute, Jewish General;Hospital, Montreal, Quebec, Canada.;Service de Pharmacologie Medicale et Clinique, Centre Midi-Pyrenees de;PharmacoVigilance, Pharmacoepidemiologie et d'Informations sur le Medicament,;Centre Hospitalier Universitaire, Faculte de Medecine, Toulouse, France.;Unite clinique de Pharmacologie psychiatrique, Faculte de Medecine, Centre;Hospitalier Universitaire, Toulouse, France.;Geri-PARTy Research Group, Department of Psychiatry, Jewish General Hospital,;McGill University, Montreal, Quebec, Canada.;Aix Marseille Univ, APHM, INSERM, Inst Neurosci Syst, Service de Pharmacologie;Clinique et Pharmacovigilance, Marseille, France.;Department of Epidemiology, Biostatistics and Occupational Health, McGill;University, Montreal, Quebec, Canada.;Department of Neurology and Neurosurgery, McGill University, Montreal, Quebec,;Canada.|